Business Wire

Decision Intelligence Highlighted at Israel Hi-Tech Conference 2022

Share

Israel Hi-Tech Conference 2022 recently put Decision Intelligence center stage, with main stage presentations from Omri Kohl, the CEO and co-founder of Pyramid Analytics (Pyramid), a pioneering decision intelligence platform provider, and Dr. Lorien Pratt, Chief Scientist at Quantellia and the co-inventor of Decision Intelligence. Their presentations set out how the growing field of Decision Intelligence is taking artificial intelligence (AI) and analytics to the next level, and formed part of a packed agenda of events. This year’s conference focused on the opportunities created by AI and featured speakers from technology giants including Dell, Google, and NVIDIA.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220908005304/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Omri Kohl, Chief Executive Officer, and Co-Founder, Pyramid Analytics: “Decision Intelligence is built on the principle that you should not need a background in data science to access the benefits of advanced analytics. At Pyramid, we are committed to automating the decision process to empower anyone to make faster, more intelligent decisions with any data, for any person and any analytics need." (Photo: Business Wire)

Key Points:

  • Dr. Pratt outlined why Decision Intelligence is the link to connect decision makers with data and analytics, addressing the persistent underutilization of data-driven insights by businesses today.
  • Decision Intelligence platforms have the potential to solve a range of previously vexing problems such as climate change, societal inequalities, and complex business problems.
  • Unlike some ML-driven analytic tools concerned with completely automating analysis, Decision Intelligence platforms augment human cognition.
  • According to Gartner® research, Decision Intelligence will be used by one-third of all large organizations by next year.
  • Global Spending on Big Data and Analytics Solutions is surging: IDC estimates it hit $215.7 billion in 2021 and it will have 12.8% compound annual growth rate 2021-2025.

Dr. Pratt is a leading voice on AI and analytics today. With a background in machine learning, she spearheaded several major breakthroughs, most notably the invention of transfer learning. Today she is one of the leading visionaries on Decision Intelligence, having recently published a book on the topic: How Decision Intelligence Connects Data, Actions and Outcomes for a Better World.

Her address at Hi-Tech Conference 2022 outlined a persistent problem in the tech industry: technology is not solving the problems we need it to. AI and Machine learning revolutionized how computers were programmed, allowing for rapid process and analysis of data at scale. However, Dr. Pratt told the attendees, ML can only label and predict, it cannot model causal connections on its own. It does not join up actions and outcomes, leaving a fundamental gap between analytics and decision makers.

Decision Intelligence is crucial in moving from actions to outcomes. Dr. Pratt underlined how it bridges the gap from decision makers to data analytics and AI, providing them with rapid access to the insights they need to tackle the most pressing, complex, and often unsolved, issues we face today. Decision Intelligence is about letting humans work together with analytics, data, and more to use AI for strategic, operational, and tactical decisions, from the C Suite to the front line.

A $200 Billion+ Market
The growth potential of Decision Intelligence is enormous. Gartner predicts that “more than 33%” of large organizations will be using Decision Intelligence by 2023. Similarly, worldwide spending on big data and business analytics (BDA) solutions was forecast to reach $215.7 billion in 2021, an increase of 10.1% over 2020, according to a recent update from IDC. The compound annual growth rate (CAGR) for global BDA spending over the 2021-2025 forecast period is predicted to be 12.8%.

Pyramid is helping to define this growing market. On the back of a recent oversubscribed US $120M Series E funding round, Omri Kohl appeared at this year’s conference in Israel to showcase Pyramid Analytics’ commitment to ensure everyone – even if they don’t have a technical background in analytics or data science – can access faster and more informed decisions.

Decision Intelligence is the Next Big Data Analytics Innovation
Artificial Intelligence (AI) is an increasingly important analytics technology. But AI to date is limited to highly-trained practitioners, and until now, there has been no easy way to integrate the essential AI components of Data Prep, Business Analytics, and Data Science. Pyramid solutions meet this need: its Decision Intelligence solutions go beyond traditional business intelligence tools such as Microsoft Power BI, Qlik, and Tableau. Pyramid’s platform lowers the skills barrier by automating the highly technical work needed to prepare and analyze data and create and share reports and dashboards.

In particular, the Pyramid Decision Intelligence Platform delivers data-driven insights for anyone to make faster, more intelligent decisions. The Pyramid Platform provides instant access to any data, enables automated governed self-service for any person, and serves any analytics need, from the simple to the sophisticated. By uniquely combining Data Prep, Business Analytics, and Data Science with AI guidance in a single environment, the Pyramid Platform reduces cost and complexity while accelerating growth and innovation. This enables a strategic, organization-wide approach to Business Intelligence and Analytics.

Quotes
Omri Kohl , Chief Executive Officer, and Co-Founder, Pyramid Analytics: “Decision Intelligence is built on the principle that you should not need a background in data science to access the benefits of advanced analytics. At Pyramid, we are committed to automating the decision process to empower anyone to make faster, more intelligent decisions with any data, for any person and any analytics need. It was a true pleasure to hear Dr. Pratt’s motivating talk at this year’s conference. She made Decision Intelligence, and its benefits, real and relatable for the audience, and everyone left the talk motivated to turn her inspiring words into reality.”

Dr. Lorien Pratt , Chief Scientist and Co-Founder, Quantellia LLC: “The shift represented by Decision Intelligence can be thought of in a similar manner to when we took computer technology out of hidden rooms and onto our desks and into our pockets. This is a once-in-a-generation moment, democratizing access to AI and data analytics – technology once reserved exclusively for the tech giants of our age. It gives us a framework for decision makers and data scientists to come together and ensure technology can be put to work in solving problems. It is a new way of thinking for organizations: rather than starting by thinking about the data you have, it asks us all to begin by asking what outcomes we want and what actions can be taken to achieve those outcomes, and then to fit the data into this action-to-outcome pathway.

“It was my pleasure to join so many talented individuals at this year’s Hi-Tech Conference. It was a fantastic event that demonstrated that the DI and AI sector is in robust health. I cannot wait to see Decision Intelligence continue to grow and expand. Far from eliminating the human element of work, Decision Intelligence augments the capabilities of ordinary workers, empowering them to solve the biggest problem of our age.”

About Pyramid Analytics
Pyramid is what’s next in analytics. Our unified decision intelligence platform delivers insights for anyone to make faster, more intelligent decisions. The Pyramid Decision Intelligence Platform provides direct access to any data, enables governed self-service for any person, and serves any analytics need in a no-code environment. The Pyramid Platform uniquely combines Data Prep, Business Analytics, and Data Science in a single environment with AI guidance, reducing cost and complexity while accelerating growth and innovation. The Pyramid Platform enables a strategic, organization-wide approach to Business Intelligence and Analytics, from the simple to the sophisticated. Schedule a demo.

Pyramid Analytics is incorporated in Amsterdam and has regional headquarters in global innovation and business centers, including London, New York City, and Tel-Aviv. Our team lives worldwide because geography should not be a barrier to talent and opportunity. Investors include H.I.G. Growth Partners, Jerusalem Venture Partners (JVP), Sequoia Capital, and Viola Growth. Learn more at Pyramid Analytics.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Media Contact
UK

Alex Izza
Resonance
+44 759 189 9654
pyramidanalytics@resonancecrowd.com

US
Heather Racicot
Resonance
+1 360-632-5616
pyramidanalytics@resonancecrowd.com

Chas Kielt
Vice President of Global Corporate Communications, Pyramid Analytics
617.687.3371
chas.kielt@pyramidanalytics.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

A-CAP Announces Successful Divestiture of Standard de Liège SA and Immobilière du Standard de Liège SRL6.6.2025 23:32:00 EEST | Press release

Advantage Capital Holdings, LLC (“A-CAP” or “The Company”), a New York-based insurance and financial services company with over $12 billion in assets, today announced the successful divestiture of Standard de Liège SA (“Standard Liège” or the “Club”), one of Belgium's most historic soccer clubs, and Immobilière du Standard de Liège SRL, the corporate entity that owns the Club's stadium, Maurice Dufrasne Stadium, to a consortium of buyers led by Standard Liège Chief Executive Officer Giacomo Angelini. This transaction marks the end of 777 Partners’ legacy involvement with the Club and sets the stage for the Club’s future growth and success, both on and off the field. Benefits of the transaction include: Increased stability across the Club’s shareholder base, which clears the path for future investments, Operational clarity, establishing a unified direction that will allow both players and management to fully concentrate on on-field performance, ensuring that collective focus remains on

Populous Acquires Fentress Architects, Expanding Global Aviation Portfolio6.6.2025 21:00:00 EEST | Press release

Populous, the world-renowned design firm specializing in sport and entertainment venues, today announced the acquisition of Denver-based Fentress Architects, a global leader in iconic aviation projects and prominent public buildings, including convention centers, museums and government facilities. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250606849000/en/ Los Angeles International Airport. Designed by Fentress Architects. This strategic acquisition unites two of the most respected names in architecture, combining Populous’ unparalleled expertise in designing memorable experiences with Fentress’ award-winning portfolio of aviation, civic and cultural landmarks. The acquisition significantly broadens the scope and scale of services that Populous can offer clients across the globe. Bruce Miller, Populous Global Chair and CEO, commented: “We are committed to expanding the breadth of our practice. Fentress Architects has lon

Vertex Presents New Data on Benefits of ALYFTREK ® and Importance of Achieving Lower Sweat Chloride Levels at the European Cystic Fibrosis Conference6.6.2025 19:00:00 EEST | Press release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data across multiple studies demonstrating positive clinical and quality of life benefits of treatment with CFTR modulators and, in particular, ALYFTREK® (vanzacaftor/tezacaftor/deutivacaftor), which is approved in the United States and United Kingdom and is currently under review with health authorities in the EU, Canada, Australia, New Zealand and Switzerland. These data were presented at this year’s European Cystic Fibrosis Society’s (ECFS) 48th European Cystic Fibrosis Conference held June 4-7, 2025, in Milan, Italy. During the conference, the Company presented data from a pooled analysis across CFTR modulators, including ALYFTREK, which demonstrate that reduction in sweat chloride (SwCl), and therefore greater restoration of CFTR function, is associated with improved outcomes in people with cystic fibrosis (CF). For all clinical outcomes in the study, SwCl levels below 60 mmol/L were associated with greater benefit

IBSA Derma at IMCAS Asia 2025: spotlight on the future of aesthetic medicine in the 10 th Anniversary Year of NAHYCO ® Technology6.6.2025 17:00:00 EEST | Press release

IBSA Derma – the dermoaesthetic division of IBSA – once again confirms its leadership in the international aesthetic medicine landscape by participating in the 18th edition of IMCAS Asia, taking place from June 6 to 8 in Bangkok, Thailand. With over 3,000 attendees expected, the event represents a key opportunity for physicians and experts to share the latest innovations and cutting-edge advancements in aesthetic procedures and treatments, staying at the forefront of this dynamic field. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250603094257/en/ IBSA’s stand at IMCAS Asia 2025 As part of the congress, IBSA Derma will host a scientific symposium titled “The Future of Tissue Regeneration with NAHYCO® Technology. Feeling and Seeing the Results with Profhilo® Line” scheduled for Saturday, June 7, from 3:00 to 4:00 pm ICT in Room 1 - Level 2. Internationally renowned speakers – Dr. Lam Bee Lan and Prof. Ofir Artzi – will lead

HistoSonics Completes Enrollment in #HOPE4KIDNEY Trial Evaluating Non-Invasive Histotripsy to Treat Kidney Tumors6.6.2025 15:00:00 EEST | Press release

HistoSonics, Inc., the manufacturer of the Edison® Histotripsy System and novel histotripsy therapy platforms, today announced the completion of patient enrollment in its pivotal #HOPE4KIDNEY trial. This prospective, multi-center, single-arm trial is designed to evaluate the safety and effectiveness of the Edison System in destroying kidney tissue by treating primary solid kidney tumors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250606659747/en/ Edison Histotripsy System Procedure for Kidney Tumor Animation The trial enrolled patients with a single, non-metastatic solid kidney mass ≤3 cm, confirmed by imaging and biopsy. Subjects will be followed for five years post-procedure, with evaluations at multiple time points, including 14-day, 30-day, 90-day, 180-day, and annual assessments. The Edison System remains in investigational use for kidney applications and is not yet FDA-approved for this indication. Data from the #H

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye